OUR DEVELOPMENT PORTFOLIO
latest update 10 September 2018
Cardiovascular diseases
Diabetes
Cancer
Immune-
Inflammatory diseases
Neuropsychiatric diseases
Phase 1
|
Colorectal cancer, 2nd line Trifluridine/Tipiracil |
|
|
Cancer MPS1 inhibitor |
|
|
Cancer Mcl1 inhibitor |
|
|
Cancer UCART 19 |
|
|
Cancer DART 123 |
|
|
Cancer Bcl2 inhibitor |
|
|
Lung cancer, 2nd line Nanoliposomal Irinotecan |
|
|
Cancer, 1st line mPaCa / Nanoliposomal Irinotecan |
|
Ischemic stroke TAFIa inhibitor |
|
|
Chronic heart failure Anti Mir92a |
|
Muscle diseases RyR modulator |
Phase 2
|
|
Venous leg ulcer |
|
|
Colorectal cancer, 1st line Trifluridine/Tipiracil |
|
|
Osteoarthritis ADAMTS-5 |
|
Post stroke GABA antagonist |
|
|
Multiple sclerosis Anti MSRV-Env |
Phase 3
|
|
Chronic heart failure Omecamtiv meécarbil |
|
Type 2 diabetes Exenatide implant |
|
|
Lymphoma, 2nd line Pixantrone |
|
|
Autism Bumetanide |